Vaccination for experimental gliomas using GM-CSF-transduced glioma cells

Cancer Gene Therapy

Volumn 4, Issue 6, 1997, Pages 345-352

  Herrlinger, Ulrich ^a,b   Kramm, Christof M ^a,c   Johnston, Karen M ^a,d   Louis, David N ^a   Finkelstein, Dianne ^a   Reznikoff, Glen ^e   Dranoff, Glenn ^e   Breakefield, Xandra O ^a   Yu, John S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d MONTREAL GENERAL HOSPITAL   (Canada)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Gene therapy; Glioma; Granulocyte macrophage colony stimulating factor; Immunotherapy; Vaccination

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; BIOSYNTHESIS; BRAIN TUMOR; C57BL MOUSE; CELL CULTURE; CELL LINE; FEMALE; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; GLIOMA; METHODOLOGY; MOUSE; PATHOLOGY; RETROVIRUS; SURVIVAL RATE; TIME;

ANIMALS; BRAIN NEOPLASMS; CANCER VACCINES; CELL LINE; FEMALE; GENE THERAPY; GENETIC VECTORS; GLIOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; RETROVIRIDAE; SURVIVAL RATE; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031261851     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Pilkington GJ. Tumour cell migration in the central nervous system. Brain Pathol. 1994;4:157-166.
2. Kramm CM, Sena-Esteves M, Barnett FH, et al. Gene therapy for brain tumors. Brain Pathol. 1995;5:345-381.
3. Barba D, Hardin J, Sadelain M, Gage FH. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA. 1994;91:4348-4352.
4. Tapscott SJ, Miller AD, Olson JM, Berger MS, Groudine M, Spence AM. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc Natl Acad Sci USA. 1994;91: 8185-8189.
5. Jaeckle KA. Immunotherapy of malignant gliomas. Semin Oncol. 1994;21:249-259.
6. Tada M, de Tribolet N. Recent advances in immunobiology of brain tumors. J Neuro-Oncol. 1993;17:261-271.
7. Kurpad SN, Wikstrand CJ, Bigner DD. Immunobiology of malignant astrocytomas. Semin Oncol. 1994;21:149-161.
8. Yu JS, Wei MX, Chiocca EA, Martuza RL, Tepper RI. Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res. 1993;53:3125-3128.
9. Tjuvajev J, Gansbacher B, Desai R, et al. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-γ. Cancer Res. 1995;55:1902-1910.
10. Lichtor T, Glick RP, Kim TS, Hand R, Cohen EP. Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg. 1995;83:1038-1044.
11. Fahkrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Nail Acad Sci USA. 1996;93:2909-2914.
12. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
13. Saito S, Bannerji R, Gansbacher B, et al. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res. 1994;54:3516-3520.
14. Vieweg J, Rosenthal FM, Bannerji R, et al. Immunotherapy of prostate cancer in the Dunning rat model. Use of cytokine gene modified tumor vaccines. Cancer Res. 1994; 54:1760-1765.
15. Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K, Hamada H. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res. 1996;56: 1828-1833.
16. Sampson JH, Archer GE, Ashley DM, et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci USA. 1997;93:10399-10404.
17. Yu JS, Burwick JA, Reznikoff G, Dranoff G, Breakefield XO. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor secreting melanoma cells. Hum Gene Ther. 1997;8: 1065-1072.
18. Akbasak A, Oldfield EH, Saris SC. Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro. J Neurosurg. 1991;75:922-929.
19. Ausman JI, Shapiro WR, Rail DP. Studies on the chemo-therapy of experimental brain tumors: development of an experimental model. Cancer Res. 1970;30:2394-2400.
20. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA. 1988;85:6460-6464.
21. Saris SC, Spiess P, Lieberman DM, Lin S, Walbridge S, Oldfield EH. Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg. 1992;76:513-519.
22. Pardoll DM. Paracrine cytokine adjuvants in cancer im-munotherapy. Annu Rev Immunol. 1995;13:399-415.
23. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271-296.
24. Silberstein DS, Schoof DD, Rodrick ML, Tai PC, Spry CJ, David JR, Eberlein TJ. Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells. J Immunol. 1989;142:2162-2167.
25. Graziano RF, Looney RJ, Shen L, Fanger MW. FcyR-mediated killing by eosinophils. J Immunol. 1989;142:230-235.
26. Rivoltini L, Viggiano V, Spinazze S, et al. In vitro antitumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int J Cancer. 1993;54:8-15.
27. Baldwin GC, Gasson JC, Wuan SG, Fleischmann J, Weisbart R, Oette D, Mitsuyasu RT, Golde DW. Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients. Proc Natl Acad Sci USA. 1988;85:2763-2766.
28. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med. 1994;179:1215-1224.
29. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272:60-66.